Experts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.
Mitchell Kamrava, MD
Advertisement
Articles by Mitchell Kamrava, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Frontline Sunvozertinib Improves PFS vs Chemotherapy in EGFR+ NSCLC
2
BCMA-Directed Bispecific Antibodies Navigating a New Era in Relapsed/Refractory Multiple Myeloma
3
Comparison of the 3 Most Commonly Used Modified PD-1 Inhibitors Plus Chemotherapy in Inoperable Wild-Type Non–Small Cell Lung Cancer
4
Is It Helping or Harming? A Clinician’s Guide to Cannabis Use in Oncology
5